Download PDF
Thromb Haemost 1997; 78(01): 520-522
DOI: 10.1055/s-0038-1657580
Hyperhomocysteinemia and thrombosis
Schattauer GmbH Stuttgart

Hyperhomocysteinemia as a Risk Factor for Arterial and Venous Disease. A Review of Evidence and Relevance

Godfried H J Boers
Department of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Mudd SH, Levy HL, Skovby F. 1995. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds) The metabolic and molecular basis of inherited disease. New York: McGraw-Hill: 1995. pp 1279-1327
    Google Scholar
  • 2 Boers GHJ. Homocystinuria, a risk factor of premature vascular disease. Clinical Research Series. No 3. Dordrecht-Holland/Riverton- USA: Foris Publications; 1986
    Google Scholar
  • 3 Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Audria G, Boers GHJ, Homberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine-β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31
    PubMedGoogle Scholar
  • 4 Boers GHJ, Smals AGH, Trijbels JMF, Fowler B, Bakkeren JAJM, Schoonderwaldt JC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715
    CrossrefPubMedGoogle Scholar
  • 5 Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155
    CrossrefPubMedGoogle Scholar
  • 6 Kluijtmans LAJ, van de Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, Den Heijer M, Trijbels JMF, Rosen R, Blom HJ. Molecular genetic analysis in mild hyperho-mocysteinemia: A common mutation in the methyl-enetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41
    PubMedGoogle Scholar
  • 7 Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150
    PubMedGoogle Scholar
  • 8 Sardharwalla IB, Fowler B, Robinson AJ, Komrower GM. Detection of heterozygotes for homocystinuria. Arch Dis Child 49 1974; 553-559
    CrossrefPubMedGoogle Scholar
  • 9 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57 1976; 211-215
    PubMedGoogle Scholar
  • 10 Boers GHJ, Schoonderwaldt HC, Schulte PBM, Trijbels JMF, Smals AGH, Kloppenborg PWC. Heterozygosity for homocystinuria: a risk factor of occlusive cerebrovascular disease. Clin Genet 24 1983; 300-301
    PubMedGoogle Scholar
  • 11 Boers GHJ. Hyperhomocysteinemia: a newly recognized risk factor for vascular disease. Neth J Med 45 1994; 34-41
    PubMedGoogle Scholar
  • 12 Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis Jr RB. (eds) Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker: 1992. pp 183-236
    Google Scholar
  • 13 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274 1995; 1049-1057
    CrossrefPubMedGoogle Scholar
  • 14 Daly LE, Meleady R, Graham IM. Fasting or post methionine load homocysteine: which should be measured in relation to vascular risk. (Abstract) Irish J Med Sci. 1995: 164 suppl. 15,6
    Google Scholar
  • 15 Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 (in press)
    PubMedGoogle Scholar
  • 16 Bienvenu T, Ankri A, Chadefaux B, Kamoun P. Dosage de l’homocysteine plasmatique dans l’exploration des thromboses du sujet jeune. Presse Med 20 1991; 985-988
    PubMedGoogle Scholar
  • 17 Brattström L, Tengbom L, Lagerstedt C, Israelsson B, Hultbeig B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57
    PubMedGoogle Scholar
  • 18 Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 71 1993; 337-359
    CrossrefPubMedGoogle Scholar
  • 19 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Munnucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14 1994; 1080-1083
    CrossrefPubMedGoogle Scholar
  • 20 Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandebroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Eng J Med 334 1996; 759-762
    CrossrefPubMedGoogle Scholar
  • 21 Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis. Lancet 345 1995; 882-885
    CrossrefPubMedGoogle Scholar
  • 22 Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jacobs C, Fowler B, Seligsohn U. Coexistence of heriditary homocystinuria and factor V Leiden, effect on thrombosis. N Eng J Med 334 1996; 763-768
    CrossrefPubMedGoogle Scholar
  • 23 D’Angelo A, Fermo I, d’Angelo SV. Thrombophilia, homocystinuria, and mutation of the factor V gene. (Letter) N Eng J Med 1996; 335: 289
    CrossrefPubMedGoogle Scholar
  • 24 Quéré I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene. (Letter) NEngJ Med 1996; 335: 289
    PubMedGoogle Scholar
  • 25 Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IM. Events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124
    CrossrefPubMedGoogle Scholar